Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Indonesia Energy Corporation Limited (INDO) vs BIO-TECHNE Corp (TECH) Price & Performance

Indonesia Energy Corporation LimitedTrade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Indonesia Energy Corporation Limited vs BIO-TECHNE Corp — how do they compare? Indonesia Energy Corporation Limited trades at $2.85 (market cap $42.62M), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 266.8× Indonesia Energy Corporation Limited's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Indonesia Energy Corporation Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Indonesia Energy Corporation Limited for 24 Days and BIO-TECHNE Corp for 63 Days on average.

INDOTECH
Market Cap
$42.62M$11.37B
Volume
60,3713,153,511
Sector
EnergyHealth
52-Week High
$6.74$72.61
52-Week Low
$2.49$43.31
Typical Hold Time
24 Days63 Days
Enterprise Value
$37.56M$11.40B
Dividend Yield
—0.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Indonesia Energy Corporation Limited

INDO trades at $2.77 with no recent price change, reflecting a bearish technical signal. The company reported a net loss of $5.10 million in 2025, with negative profit margins and cash flow from operations. Recent news highlights operational progress, including oil discovery at the K-29 well and participation in investment conferences.

Despite a 100% buy rating from analysts, fundamental weaknesses and negative earnings trends pose significant risks. The stock's outlook depends on successful execution of drilling operations to improve financial performance. Investors should weigh high operational risks against potential growth from new production.

BIO-TECHNE Corp

TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.

Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INDO
100% Buy0% Sell
Avg holding period · 24 Days
TECH

No sentiment data available yet.

Top news

Latest headlines on both assets

About Indonesia Energy Corporation Limited

Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.

Read more on INDO →

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH →